R-pola-mini-CHP

Phase 3Small molecule

NNordic Lymphoma Group

R-pola-mini-CHP is one of 29 small molecule programs targeting Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

LymphomaActive, not recruiting

LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

1774 competitors in Lymphoma

#DrugCompanyPhaseTrials

Velban

EEastern Cooperative Oncology Group

Preclinical

15 2

R-pola-mini-CHP

NNordic Lymphoma Group

Phase 3

1 3

Zofran

Novartis

Preclinical

2 4

Wellcovorin

GGlaxo Dba Glaxosmithkline

Preclinical

4 5

Emend

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 6

Nuvigil

NNuvo Research GmbH

Preclinical

1 7

Elitek

AAzienda U.S.L. 1 di Massa e Carrara

PEG-Intron

1 9

Systemic Therapy

Bristol-Myers Squibb

Preclinical

1 10

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 3Recruiting

Lymphoma

NCT04332822

Clinical

Trials by Indication[1]

Lymphoma1 trial

A Randomized, Multicenter, Phase III Trial Comparing Treatment With R-mini-CHOP With R-mini-CHP + Polatuzumab Vedotin in Patients With Diffuse Large Cell B Cell Lymphoma

Recruiting·NNordic Lymphoma Group·Phase 3·NCT04332822·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for R-pola-mini-CHP. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — R-pola-mini-CHP compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for R-pola-mini-CHP. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Nordic Lymphoma Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNordic Lymphoma Group

R-pola-mini-CHP

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Lymphoma1 trial

References

Drug Info

Quick Facts

Related News